

Novel COVID-19 antibody treatment

1

IGY Immune Technologies & Life Sciences (IGY Life Sciences) is striving to be the global leader in the development and manufacture of IgY antibodies, which are polyclonal antibodies used in animal and human health. Following the outbreak of the Covid-19 virus, the Canada-based company has teamed up with clinical data and regulatory experts MMS to further the development of IGY-110, an anti-CoV-2 therapeutic antibody with a focus on a nasal spray application. This novel approach of an IgY antibody in a nasal spray will be complementary to any vaccine developed, says Terry Dyck, the President & CEO of IGY Life Sciences.

IgY antibodies are polyclonal antibodies predominantly found in chicken blood and egg yolk. They have been well understood by the science community for many decades and can be produced against numerous targets, whether bacterial, viral, fungal and even cancer

related immunotherapy. IGY Life Sciences is a leader in this space: its proprietary extraction technology can purify IgY at an industry leading purity of up to 99% pure IgY, and the company's own GMP manufacturing facility can produce scalable quantities for both animal and human health applications.

IGY Life Sciences currently has two consumer health products on the market and is also in the process of developing a product for African Swine Fever, a virus that has led to the culling of hundreds of millions of pigs in Asia and Europe.

IGY-110, an anti-CoV-2 therapeutic antibody, is a polyclonal antibody targeting the spike proteins of the coronavirus. Mr. Dyck expects IGY-110 will be capable of neutralizing Covid-19, other coronavirus strains and common cold viruses such as adenoviruses. "Since IgY is an antibody it would have an immediate effect while vaccines need 7-10 days for the immune system to make the antibodies," he points out.

The company is developing IGY-110 to be administered as a nasal spray. The intranasal delivery approach is supported by recent major scientific publications that have found that SARS-CoV-2 infects and replicates in the nasal cavity to a greater degree and

less well in cells lower down in the respiratory tract, including the lungs. In addition, IgY would likely replace vaccines in immunocompromised or immunodeficient individuals.

MMS will provide regulatory advice from a scientific perspective to best position IGY-110 for expedited FDA review. "This is a critical step and sets the stage to start investigations in COVID-19 patients," says Mr. Dyck. "Once in clinical development, MMS will apply their unique data acceleration model to deliver efficiency for data collection and analysis across all study phases and global regions."

IGY-110 is currently in preclinical trials at Health Canada's National Microbiology Lab in Winnipeg Manitoba. IGY Lifesciences anticipates that IGY-110 will move through the preclinical phase rapidly since IgY antibodies are established with GRAS (Generally Regarded as Safe) status and complete the Investigational New Drug (IND) enabling work by early Fall. With positive preclinical results, we expect to start human trials no later than the first half of 2021.



IGY Life Sciences

Website: www.igyilifesciences.com